Nikolay P Nikolov1, Gabor G Illei. 1. Sjögren's Syndrome Clinic, National Institute of Dental and Craniofacial Research (NIDCR), Molecular Physiology and Therapeutics Branch, National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.
Abstract
PURPOSE OF REVIEW: To summarize recent developments in our understanding of the pathogenesis of Sjögren's syndrome with a focus on the relationship between inflammation and exocrine dysfunction. RECENT FINDINGS: Animal models demonstrated the complex interactions between immunologic and nonimmunologic mechanisms in Sjögren's syndrome. Activation of the innate immune system can lead to exocrine dysfunction before or without significant inflammation, whereas in other models, salivary gland function is preserved despite intense inflammatory infiltrates. Primary or inflammation-related abnormalities in water channels contribute to the exocrinopathy. Activation of the innate immunity in patients is demonstrated by the upregulation of type-1 interferon-regulated genes (interferon signature) in peripheral blood and salivary glands and abnormal expression of B cell-activating factor and its receptors. Nonimmune mechanisms that may contribute to exocrine dysfunction include local and systemic androgen deficiency and autonomic nervous system dysfunction. Autoantibodies against the muscarinic acetylcholine receptors would provide a link between autoimmunity and exocrine dysfunction, but the data on the presence, frequency and physiologic affect of these antibodies remain controversial. SUMMARY: Recent discoveries from studies in patients with Sjögren's syndrome and animal models suggest a complex interplay between genetic factors, environmental and stochastic events that involve innate and adaptive immunity, hormonal mechanisms and the autonomic nervous system. Some of these findings suggest that exocrine gland dysfunction may precede autoimmunity or represent a process independent from inflammation in the pathogenesis of Sjögren's syndrome.
PURPOSE OF REVIEW: To summarize recent developments in our understanding of the pathogenesis of Sjögren's syndrome with a focus on the relationship between inflammation and exocrine dysfunction. RECENT FINDINGS: Animal models demonstrated the complex interactions between immunologic and nonimmunologic mechanisms in Sjögren's syndrome. Activation of the innate immune system can lead to exocrine dysfunction before or without significant inflammation, whereas in other models, salivary gland function is preserved despite intense inflammatory infiltrates. Primary or inflammation-related abnormalities in water channels contribute to the exocrinopathy. Activation of the innate immunity in patients is demonstrated by the upregulation of type-1 interferon-regulated genes (interferon signature) in peripheral blood and salivary glands and abnormal expression of B cell-activating factor and its receptors. Nonimmune mechanisms that may contribute to exocrine dysfunction include local and systemic androgen deficiency and autonomic nervous system dysfunction. Autoantibodies against the muscarinic acetylcholine receptors would provide a link between autoimmunity and exocrine dysfunction, but the data on the presence, frequency and physiologic affect of these antibodies remain controversial. SUMMARY: Recent discoveries from studies in patients with Sjögren's syndrome and animal models suggest a complex interplay between genetic factors, environmental and stochastic events that involve innate and adaptive immunity, hormonal mechanisms and the autonomic nervous system. Some of these findings suggest that exocrine gland dysfunction may precede autoimmunity or represent a process independent from inflammation in the pathogenesis of Sjögren's syndrome.
Authors: Manon E Wildenberg; Cornelia G van Helden-Meeuwsen; Joop P van de Merwe; Hemmo A Drexhage; Marjan A Versnel Journal: Eur J Immunol Date: 2008-07 Impact factor: 5.532
Authors: N-Y Koo; J Li; S-M Hwang; S-Y Choi; S J Lee; S-B Oh; J-S Kim; E B Lee; Y W Song; K Park Journal: Rheumatology (Oxford) Date: 2008-04-09 Impact factor: 7.580
Authors: T Mandl; V Granberg; J Apelqvist; P Wollmer; R Manthorpe; L T H Jacobsson Journal: Rheumatology (Oxford) Date: 2008-04-14 Impact factor: 7.580
Authors: Vanessa Schegg; Monique Vogel; Svetlana Didichenko; Michael B Stadler; Zsuzsanna Beleznay; Stephan Gadola; Christine Sengupta; Beda M Stadler; Sylvia M Miescher Journal: Biologicals Date: 2008-01-14 Impact factor: 1.856
Authors: Fin Z J Cai; Sue Lester; Tim Lu; Helen Keen; Karyn Boundy; Susanna M Proudman; Anne Tonkin; Maureen Rischmueller Journal: Arthritis Res Ther Date: 2008-03-07 Impact factor: 5.156
Authors: Saeed Khalili; Younan Liu; Yoshinori Sumita; Ola M Maria; David Blank; Sharon Key; Eva Mezey; Simon D Tran Journal: Int J Biochem Cell Biol Date: 2010-08-21 Impact factor: 5.085
Authors: Shen Hu; Kai Gao; Rodney Pollard; Martha Arellano-Garcia; Hui Zhou; Lei Zhang; David Elashoff; Cees G M Kallenberg; Arjan Vissink; David T Wong Journal: Arthritis Care Res (Hoboken) Date: 2010-07-08 Impact factor: 4.794
Authors: Kwong Tai Cheng; Ilias Alevizos; Xibao Liu; Wiliam D Swaim; Hongen Yin; Stefan Feske; Masatsugu Oh-hora; Indu S Ambudkar Journal: Proc Natl Acad Sci U S A Date: 2012-08-17 Impact factor: 11.205
Authors: Nezam Altorok; Patrick Coit; Travis Hughes; Kristi A Koelsch; Donald U Stone; Astrid Rasmussen; Lida Radfar; R Hal Scofield; Kathy L Sivils; A Darise Farris; Amr H Sawalha Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995